hcv in 3

HCV-IN-3 is a hepatitis C virus (HCV) NS3/4a protein inhibitor with an IC50 of 20 μM and a Kd of 29 μM.

HCVNS5B polymerase-IN-3 (Compound 30a) is an inhibitor of the hepatitis C virus NS5B polymerase. It demonstrates anti-HCV activity with an EC50 of 0.23 μM in Huh7 replicon cell lines, showing no significant cytotoxicity. HCVNS5B polymerase-IN-3 is applicable in hepatitis C virus research.

HCV-IN-30 is an HCV NS5A replication complex inhibitor (IC50s: 901 and 102 nM for genotypes 1a and 1b replicons).

HCV-IN-38 is a selective, potent, orally active hepatitis C virus (HCV) inhibitor with an EC50 value of 15 nM and an SI value of 431. HCV-IN-38 has a good safety profile and oral pharmacokinetics, exhibiting high anti-HCV activity and low cytotoxic effects.

HCV-IN-35 is a potent inhibitor of HCV and shows potential for infectious disease research.

HCV-IN-36 is an orally active HCV entry inhibitor that exhibits good antiviral activity (EC50: 0.016 μM, CC50 (half of the maximum cytotoxic concentration): 8.78 μM).

HCV-IN-33 [Compound (S)-3i] is an inhibitor of HCV entry.

HCV-IN-34 is an orally active HCV entry inhibitor. HCV-IN-35 exhibits good antiviral efficacy (EC50: 0.010 μM, CC50 (half of the maximum cytotoxic concentration): 7.50 μM).

HCV-IN-37 is a potent inhibitor of HCV. HCV-IN-37 is able to persist in rat plasma after oral administration to rats at a single dose of 15 mg/kg. The high potency of the active derivative HCV-IN-37 is mainly driven by the inhibition of the entry phase of the virus.

HCV-IN-31 is a HCV inhibitor with an EC50/EC95 of 15.7 μM.

2',3'-Isopropylideneuridine is a nucleoside derivative that has shown antiviral activity in several studies, particularly against members of the Flaviviridae family (Flaviviruses), such as Hepatitis C virus (HCV).

Beclabuvir is an allosteric inhibitor that binds to thumb site 1 of the HCV NS5B RNA-dependent RNA polymerase, inhibiting recombinant NS5B proteins from HCV genotypes 1, 3, 4, and 5 (IC50 < 28 nM).

DDX3-IN-1 (Compound 16f) is a DDX3 (DEAD box polypeptide 3) inhibitor (IC50 >100 μM) with antiviral activity against HIV and HCV, with EC50 values of >50 and >36 μM, respectively.

HCV-IN-7 is an orally active and potent pan-genotypic HCV NS5A inhibitor (IC50s: 3-47 pM) with a superior pan-genotypic profile, good pharmacokinetic properties, and favorable liver uptake.

HCV-IN-7 hydrochloride is an orally active and potent pan-genotypic HCV NS5A inhibitor [IC50s: 3-47 pM], exhibiting a superior pan-genotypic profile, a good pharmacokinetic profile, and favorable liver uptake.

Ciluprevir is an effective and selective HCV NS3 protease inhibitor with proven antiviral effect in humans. Ciluprevir may be an antiviral agent for individuals infected with non-genotype-1 HCV. In vitro sensitivity studies with Ciluprevir showed a decrea

3′-Deoxy CTP trisodium is the sodium salt form of 3′-Deoxy CTP. This compound is a nucleotide analog known as a chain terminator. By lacking a 3′-hydroxyl group, it causes chain termination and inhibits the RNA synthesis activity of the HCV non-structural protein (NS5B) polymerase, thereby blocking viral replication. 3′-Deoxy CTP trisodium is utilized in the study of chain termination mechanisms of HCV polymerase and the development of antiviral drugs.

Paritaprevir free base (ABT-450) is an orally bioavailable, synthetic acylsulfonamide inhibitor of the hepatitis C virus (HCV) protease complex comprised of non-structural protein 3 and 4A (NS3/NS4A), with potential activity against HCV genotype 1. Upon administration, paritaprevir reversibly binds to the active center and binding site of the HCV NS3/NS4A protease and prevents NS3/NS4A protease-mediated polyprotein maturation. This disrupts both the processing of viral proteins and the formation of the viral replication complex, which inhibits viral replication in HCV genotype 1-infected host cells.

6-Hydroxypyridin-3-ylboronic acid is a heterocyclic building block.1,2It has been used in the synthesis of non-nucleoside inhibitors of hepatitis C virus (HCV) RNA-dependent RNA polymerase nonstructural protein 5B (NS5B).16-Hydroxypyridin-3-ylboronic acid has also been used in the synthesis of mammalian target of rapamycin (mTOR) inhibitors.2 1.Hendricks, R.T., Spencer, S.R., Blake, J.F., et al.3-Hydroxyisoquinolines as inhibitors of HCV NS5b RNA-dependent RNA polymeraseBioorg. Med. Chem. Lett.19(2)410-414(2009) 2.Verheijen, J.C., Richard, D.J., Curran, K., et al.Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and sselective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): Optimization of the 6-aryl substituentJ. Med. Chem.52(24)8010-8024(2009)

Ribavirin-13C5 is intended for use as an internal standard for the quantification of ribavirin by GC- or LC-MS. Ribavirin (T0684) is an antiviral guanosine nucleoside analog.1,2Upon entry into cells, ribavirin is metabolized to an active triphosphate form that induces viral RNA chain termination and inhibits viral polymerases. It reduces replication in a panel of seven RNA and four DNA viruses in Vero cells (EC50s = 2-95 μg/ml).3Ribavirin also reduces replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Vero cells (EC50= 109.5 μM).4Aerosol administration of ribavirin (30 mg/kg) reduces mortality in a mouse model of influenza A infection.5Formulations containing ribavirin have been used in the treatment of respiratory syncytial virus (RSV), hepatitis C virus (HCV), and viral hemorrhagic fevers.

Daclatasvir (EBP 883) (BMS-790052) is a highly selective inhibitor of HCV NS5A with EC50 of 9-50 pM, for a broad range of HCV replicon genotypes and the JFH-1 genotype 2a infectious virus in cell culture. Phase 3.

Beclabuvir, also known as BMS-791325, is an allosteric inhibitor that binds to thumb site 1 of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase. BMS-791325 inhibits recombinant NS5B proteins from HCV genotypes 1, 3, 4, and 5 at 50% inhibitory concentrations (IC50) below 28 nM. In cell culture, BMS-791325 inhibited replication of HCV subgenomic replicons representing genotypes 1a and 1b at 50% effective concentrations (EC50s) of 3 nM and 6 nM, respectively, with similar (3 to 18 nM) values for genotypes 3a, 4a, and 5a. B

NS5A-IN-3 (Compound 15) is a potent NS5A inhibitor with high efficacy against HCV genotype 1b, enhanced activity towards genotype 3a (GT 3a), and substantial metabolic stability. It exhibits superior resistance barrier compared to daclatasvir in genotype 1b [1].

PSI-353661 (GS-558093), a purine nucleotide NS5B polymerase inhibitor, is effective against HCV infection, displaying EC90 values of 8 nM and 11 nM for wild-type and S282T resistant HCV replicons, respectively. It is capable of generating high concentrations of the active triphosphate form in primary human hepatocytes [1] [3].